MI-mAbs (@MI_mAbs) header
MI-mAbs (@MI_mAbs) profile picture
Marseille, France
Joined March 2019
Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)Photo by MI-mAbs (@MI_mAbs)
The pre-industrial demonstrator @MIMABS announce the start of operations of MImAbs SAS, an #immunotechnology company specializing in generation and validation of therapeutic #antibodies against #cancer and inflammatory diseases bit.ly/3rxEqE9 @univamu @RegionSudInvest
5
4
Le démonstrateur préindustriel @MimAbs donne naissance à MImAbs SAS: société de service en #immunotechnologie spécialisée dans la génération et la validation de nouveaux #anticorps thérapeutiques bit.ly/3rxEqE9 @univamu @RegionSudInvest
8
16
An integrated analysis of #BispecificAntibodies in complex with #antigens (SEC/MALS, native MS, MS-based footprinting, epitope characterization) can provide molecular details of binding mechanisms #GuodongChen et al. @an_chem bit.ly/305Gw1Z
DLL3/CD3 #BispecificAntibody specifically redirects T cells to lyse #SCLC cells expressing Delta-like ligand 3 and leads to #tumor regression in an in vivo model #SusanneHipp et al. @CCR_AACR bit.ly/2V80wPI
Accelerate the development of a #MonoclonalAntibody at the time of #COVID19 pandemic. Here the key sequence covering from lead identification to phase 1 clinical study @Vir_Biotech @NatureBiotech go.nature.com/2VGnrTg
The @US_FDA granted accelerated approval to #Trodelvy #sacituzumabgovitecan-hziy, the first #AntibodyDrugConjugate that targets Trop-2, for treatment of #mTNBC #BreastCancer bit.ly/2XYzOLW
A tripartite β-lactamase enzyme assay in #Ecoli could assess aggregation propensity of #antibody fragments early in #DrugDevelopment and improve #antibody #developability | #DavidCLowe #DavidJBrockwell et al. @NatureComms | go.nature.com/2K6yZIO
Following the government’s stipulations to limit the spread of #Covid19, @MI_mAbs laboratories have closed. Nevertheless, part of the team is still on board and will be available to answer to your questions. bit.ly/3aNl1Hv
1
We will participate (digitally) at #BioSpringEurope next week. Please contact us to organize a (virtual!) meeting during this event. mimabs.org/upcoming-event/ev…
1
3
#BIOEuropeSpring will be delivered as a fully #digital event, contact @Mimabs's team to organize a (virtual!) meeting during this event ! mimabs.org/upcoming-event/ev…
2
1
MI-mAbs retweeted
CP : médicaments de thérapie innovante : une filière dynamique et bien implantée en France avec 36 sociétés. => ow.ly/mb7Y50yqflE
One of the 2019 highlights of @US_FDA #DrugApprovals: 3 new #AntibodyDrugConjugates, leading to a total of 7 FDA-approved #ADCs, all for the treatment of #cancer. Full analysis of 2019 approvals by #BdelaTorre & @Falbericio @Molecules_MDPI | bit.ly/2uMc95g
7
3
To avoid toxicity of #pyrrolobenzodiazepine #IVlahov et al made a pro-PBD2 #prodrug that becomes active inside target cells; subnanomolar activity + good specificity when conjugated to folate. What about in an #antibodydrugconjugate? #BioorgMedChemLett | bit.ly/37nF2SA
4
L'équipe de @MIMABS est fière d’avoir participé au projet en gérant la #production et l'#humanisation de l'#anticorps anti-#CD146
3
2
#MIDay #LungCancer "In the #clinic, the bigger the team, the higher the chances of success for #patients" @Barlesi @univamu @GustaveRoussy @immunopole
3
6
🔬 #Marseille est une des capitales mondiales de la recherche contre le #cancer, en particulier en immuno-oncologie. Pour le #MIday, jeudi, un comité d’experts répond au public et décortique 10 idées reçues sur le cancer du poumon. Les détails ➡️ tinyurl.com/vwvh36m
15
22
#WebinarReplay Want to learn about #ADCs? “State of the art ADC validation” our webinar replay is available here : bit.ly/398Ihya @MI_mAbs
Come and meet us at Toulouse Onco Week and do not miss @MI_mAbs 's presentation this Wednesday ! #TOW2020 | @TOW_2020 toulouse-onco-week.org/
1
4